Data compiled by Redley Lamar · ChainSifter Intelligence
5Suppliers
9Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
InMed Pharmaceuticals Inc. (INM) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
16Total relationships
4Distinct source URLs
5High confidence
0.734Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
InMed Pharmaceuticals Inc. Suppliers
Ticker
Name
Confidence
Evidence
UNIVERSITY-OF-BRITISH-COLUMBIA
UNIVERSITY-OF-BRITISH-COLUMBIA
92%
On May 31, 2017, we signed a Technology Assignment Agreement with the University of British Columbia whereby we retain sole worldwide rights to all patents emergent from the technology under developm…
ALMAC-GROUP-UK
ALMAC-GROUP-UK
90%
we entered into a separate process development collaboration by way of a Master Service Agreement with the Almac Group (UK)(“Almac”), a seasoned GMP pharmaceutical CDMO
these financial institutions, there can be no assurance that there will not be additional bank failures or issues in the broader financial system. Likewise, there is no guarantee that any of the U.S.…
Reciprocal relationship from FISI graph: Reciprocal relationship from INM graph: these financial institutions, there can be no assurance that there will not be additional bank failures or issues in t…
Reciprocal relationship from VSAT graph: using the effective interest method. Fees incurred with other parties are expensed as incurred. Debt issuance costs related to the Company’s revolving credit …
InMed Pharmaceuticals Inc. Customers
Ticker
Name
Confidence
Evidence
BAYMEDICA-LLC
BAYMEDICA-LLC
90%
Specifically, certain aspects of BayMedica's commercial business and its inventory of rare, non-intoxicating cannabinoids would be prohibited under the Act if it becomes effective as planned on Novem…
Reciprocal relationship from FISI graph: Reciprocal relationship from INM graph: these financial institutions, there can be no assurance that there will not be additional bank failures or issues in t…
these financial institutions, there can be no assurance that there will not be additional bank failures or issues in the broader financial system. Likewise, there is no guarantee that any of the U.S.…
ALMAC-GROUP
ALMAC-GROUP
62%
y results from the Phase 2 clinical trial (755-201-EB) for the treatment of symptoms in patients with EB. Rare Cannabinoid Products in the Health and Wellness Sector BayMedica has a revenue-generatin…
CANADIAN-DEPOSIT-INSURANCE-CORPORATION
CANADIAN-DEPOSIT-INSURANCE-CORPORATION
62%
perience. Expected credit losses on our accounts receivable were $0 and $ 66,775 as at June 30, 2024 and 2023 respectively. We had $ 66,775 and $ 0 of write-offs during the year ended June 30, 2024 a…
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
for the nine months ended March 31, 2026, as compared to the nine months ended March 31, 2025. The increase primarily results from the increase in our average cash on hand during the current year. Fi…
NEURODEGENERATIVE-DISEASES-BRAND-COMPANY
NEURODEGENERATIVE-DISEASES-BRAND-COMPANY
62%
s this group of individuals that will help optimize our chances for success. Scope of research and robust pharmaceutical pipeline Over several years of dedicated research, InMed has built a robust pi…
STEM-PHARM-INC
STEM-PHARM-INC
62%
ins an unmet medical need and a new treatment option may help solve this multifactorial disease. We have completed a Phase 2 clinical trial of INM-755 (cannabinol) cream studying its safety and effic…
SWEETNAM-CONSULTING-INC
SWEETNAM-CONSULTING-INC
62%
ed in the determination of research & development accruals. Actual results could differ from those estimates. Basis of Consolidation These consolidated financial statements include the accounts of th…
InMed Pharmaceuticals Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
INM-DEBT
Debt stack $29,312
90%
Market cache reports total debt of $29,312.
INM-DEBT-10289
Warrants outstanding: 700
90%
xbrl warrant detail from xbrl 2025-06-30.
InMed Pharmaceuticals Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for InMed Pharmaceuticals Inc..
InMed Pharmaceuticals Inc. Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for InMed Pharmaceuticals Inc..
InMed Pharmaceuticals Inc. Extended Supply Chain Network
